lisuride has been researched along with Parkinson Disease, Secondary in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (36.84) | 18.7374 |
| 1990's | 11 (57.89) | 18.2507 |
| 2000's | 1 (5.26) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, JF; Herm, L; Kalda, A; Rinken, A; Zharkovsky, A | 1 |
| Marsden, CD; Parkes, JD; Schachter, M; Smith, B; Wilson, A | 1 |
| Akai, T; Kuno, S; Mizuta, E; Yamaguchi, M | 1 |
| Goldhammer, Y; Sadeh, M | 1 |
| Cesaro, P; Hantraye, P; Maziere, M; Peschanski, M; Riche, D; Varastet, M; Willer, JC | 1 |
| Brotchie, JM; Crossman, AR; Henry, B | 2 |
| Fukuda, T; Irifune, M; Iwata, S; Kaseda, S; Nomoto, M; Osame, M | 1 |
| Halbhübner, K; Herken, H; Loos, D | 1 |
| Halbhübner, K; Herken, H; Kehr, W; Loos, D | 1 |
| Kunow, M; Löschmann, PA; Wachtel, H | 2 |
| Filip, V; Hálková, E; Karen, P; Marsálek, M | 1 |
| Gershanik, O; Luquin, MR; Obeso, JA; Scipioni, O; Vaamonde, J | 1 |
| Horowski, R; Jähnig, P; Jenner, P; Lange, KW; Löschmann, PA; Marsden, CD; Wachtel, H | 1 |
| Kito, S; Matsubayashi, H; Miyoshi, R; Mizuno, K; Nitta, K; Tahara, E; Yamamura, Y | 1 |
| Lees, A; Stern, G; Stibe, C | 1 |
| Bustos, JC; de Yebenes, JG; Fahn, S; Jackson-Lewis, V; Jorge, P; Lovelle, S; Magariños, C; Martinez, A; Mena, MA; Reiriz, J | 1 |
| Bankiewicz, K; Brücke, T; Harvey-White, J; Kopin, I | 1 |
2 trial(s) available for lisuride and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Treatment of extrapyramidal side effects with terguride.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Lisuride; Male; Middle Aged; Neurologic Examination; Parkinson Disease, Secondary; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology | 1992 |
Subcutaneous infusion of apomorphine and lisuride in the treatment of parkinsonian on-off fluctuations.
Topics: Adult; Aged; Apomorphine; Clinical Trials as Topic; Ergolines; Humans; Infusion Pumps; Lisuride; Middle Aged; Parkinson Disease, Secondary | 1987 |
17 other study(ies) available for lisuride and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Co-administration of the partial dopamine D2 agonist terguride with L-dopa attenuates L-dopa-induced locomotor sensitization in hemiparkinsonian mice.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Benzazepines; Caffeine; Corpus Striatum; Dopamine Agonists; Drug Therapy, Combination; Guanosine 5'-O-(3-Thiotriphosphate); Levodopa; Lisuride; Male; Mice; Mice, Inbred C57BL; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Random Allocation; Receptors, Dopamine D1; Receptors, Dopamine D2; Sulfur Radioisotopes | 2009 |
Lisuride in parkinsonism.
Topics: Administration, Oral; Aged; Benzimidazoles; Chorea; Domperidone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Female; Growth Hormone; Humans; Injections, Intravenous; Lisuride; Male; Middle Aged; Paralysis; Parkinson Disease; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary; Piperidines; Prolactin | 1981 |
Effects of terguride, a partial D2 agonist, on MPTP-lesioned parkinsonian cynomolgus monkeys.
Topics: Aggression; Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Dopamine Agents; Haloperidol; Lisuride; Macaca fascicularis; Motor Activity; MPTP Poisoning; Parkinson Disease, Secondary; Receptors, Dopamine D2; Time Factors | 1993 |
Extrapyramidal syndrome responsive to dopaminergic treatment following recovery from central pontine myelinolysis.
Topics: Basal Ganglia Diseases; Biperiden; Carbidopa; Chlorthalidone; Coma; Drug Therapy, Combination; Female; Humans; Hypertension; Hyponatremia; Levodopa; Lisuride; Middle Aged; Neurologic Examination; Parkinson Disease, Secondary; Pons; Quadriplegia; Saline Solution, Hypertonic; Tomography, X-Ray Computed | 1993 |
Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons.
Topics: Animals; Behavior, Animal; Blinking; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Electromyography; Electrophysiology; Female; Immunohistochemistry; Lisuride; Male; Mesencephalon; MPTP Poisoning; Nerve Fibers; Papio; Parkinson Disease, Secondary; Postural Balance; Posture; Tremor | 1993 |
Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Behavior, Animal; Bromocriptine; Clonidine; Disease Models, Animal; Dopamine; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Levodopa; Lisuride; Locomotion; Male; Mazindol; Methoxydimethyltryptamines; Oxidopamine; Parkinson Disease, Secondary; Prosencephalon; Rats; Rats, Sprague-Dawley; Sympatholytics; Tritium; Yohimbine | 1998 |
[Dermal application of lisuride on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset and on cases with Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Cutaneous; Aged; Animals; Antiparkinson Agents; Callithrix; Circadian Rhythm; Disease Models, Animal; Dopamine Agonists; Female; Humans; Lisuride; Male; Middle Aged; Motor Activity; Parkinson Disease; Parkinson Disease, Secondary; Time Factors; Treatment Outcome | 1998 |
Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Topics: Animals; Autoradiography; Behavior, Animal; Bromocriptine; Dopamine Agents; Dopamine Agonists; Dopamine Uptake Inhibitors; Enkephalins; In Situ Hybridization; Levodopa; Lisuride; Male; Mazindol; Medial Forebrain Bundle; Neostriatum; Oligonucleotide Probes; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; Radioligand Assay; Rats; Rats, Sprague-Dawley; RNA, Messenger | 1999 |
Experimental neuropathy with Parkinson-like muscular rigidity. A suitable model for testing dopaminergic agonists and neuroleptic drugs.
Topics: 6-Aminonicotinamide; Animals; Antipsychotic Agents; Baclofen; Brain; Brain Chemistry; Bromocriptine; Central Nervous System Diseases; Disease Models, Animal; Dopamine; Drug Evaluation, Preclinical; Electromyography; Gluconates; Levodopa; Lisuride; Male; Motor Neurons; Muscle Contraction; Niacinamide; Parkinson Disease, Secondary; Rats; Reserpine; RNA; Spinal Cord; Sugar Phosphates | 1978 |
Action of dopamine agonists on parkinson-like muscle rigidity induced by 6-aminonicotinamide.
Topics: 6-Aminonicotinamide; Animals; Brain Chemistry; Corpus Striatum; Diencephalon; Dihydroxyphenylalanine; Electromyography; Levodopa; Limbic System; Lisuride; Male; Muscles; Niacinamide; Parkinson Disease, Secondary; Rats; Tyrosine | 1979 |
NBQX (6-nitro-sulfamoyl-benzo-quinoxaline-dione) and CPP (3-carboxy-piperazin-propyl phosphonic acid) potentiate dopamine agonist induced rotations in substantia nigra lesioned rats.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amphetamine; Animals; Apomorphine; Dopamine Agents; Drug Synergism; Ibotenic Acid; Lisuride; Male; Neurons; Oxidopamine; Parkinson Disease, Secondary; Piperazines; Quinoxalines; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Stereotyped Behavior; Substantia Nigra; Sympathectomy, Chemical | 1992 |
Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.
Topics: Aged; Apomorphine; Chlorpromazine; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Electromyography; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Receptors, Dopamine; Sulpiride | 1992 |
Terguride stimulates locomotor activity at 2 months but not 10 months after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Disease Models, Animal; Dopamine Agents; Female; Lisuride; Male; Motor Activity; Parkinson Disease, Secondary; Time Factors | 1992 |
Synergism of NBQX with dopamine agonists in the 6-OHDA rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Drug Synergism; Lisuride; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Quinoxalines; Rats; Rats, Wistar; Stereotaxic Techniques; Substantia Nigra | 1992 |
Autoradiographic distributions of neurotransmitter receptors in the human brains of Parkinson's disease and primate models of MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain; Humans; Lisuride; Macaca; Neurotransmitter Agents; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Quinuclidinyl Benzilate; Receptors, Cholinergic; Receptors, Dopamine; Receptors, Neurotransmitter | 1987 |
Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease.
Topics: Animals; Brain; Corpus Striatum; Dopamine; Dopamine Agents; Infusion Pumps; Injections, Intraventricular; Lisuride; Macaca fascicularis; Male; Neural Pathways; Parkinson Disease, Secondary; Pergolide; Rats; Receptors, Dopamine; Selegiline; Stereotyped Behavior; Substantia Nigra | 1987 |
The partial dopamine receptor agonist terguride in the MPTP-induced hemiparkinsonian monkey model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Ergolines; Female; Lisuride; Macaca fascicularis; Parkinson Disease, Secondary; Pyridines; Receptors, Dopamine | 1988 |